The Management of Atrial fibrillation Suppression in AF-HF COmorbidity Therapy ( MASCOT ) trial enrolled 409 CRT device recipients ( 79 % men ) , who were randomly assigned to AOP ON ( n = 197 ) , versus AOP OFF ( n = 197 ) and followed up for 1 year .
